VolitionRx (United Kingdom)

VolitionRx is a multi-national epigenetics company focused on advancing the science of epigenetics to diagnose and monitor life-altering diseases. The company describes itself as dedicated to saving lives and improving outcomes for people and animals through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it develops and commercializes simple, easy-to-use, cost-effective blood tests intended to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. The company's core technology is its patented Nu.Q® platform, which uses chromosomal structures such as nucleosomes and transcription factors as biomarkers. According to the company, all tests in its portfolio detect characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially better monitoring of disease progression and a patient's response to treatment. The Nu.Q® technology is currently used for cancer applications in veterinary medicine, while the company continues to expand into human medicine through early clinical trials in cancer, sepsis and beyond. VolitionRx organizes its offerings around several product pillars, including Nu.Q® Cancer, Nu.Q® Discover, Nu.Q® NETs and Nu.Q® Vet. Nu.Q® NETs is described as a CE-marked diagnostic solution that clinicians can use to detect NETosis. Nu.Q® Vet is positioned as an affordable veterinary testing option. The company also sells recombinant nucleosomes and has developed related technologies such as Capture-Seq™. VolitionRx operates as a multi-national organization with a team of over 70 staff spanning a wide range of disciplines. Its executive team includes Cameron Reynolds as President and Group Chief Executive Officer, Terig Hughes as Group Chief Financial Officer, Gaetan Michel as Chief Operating Officer, and Jake Micallef as Chief Scientific Officer, among others. The company maintains a board of directors and describes itself as publicly listed through VolitionRx Limited. The company has pursued commercialization and clinical validation across multiple fronts, including participation in the launch of the DETECSEPS program in France, clinical validation of the Nu.Q® NETs biomarker, collaborations with partners such as Sysmex, and presentations of early-stage solid cancer detection data at scientific conferences. It also reports financial results as a public company and has announced corporate actions such as the pre-payment in full of a $7.5 million promissory note.

VolitionRx is a multi-national epigenetics company that operates through subsidiaries and is publicly listed as VolitionRx Limited. The company's name reflects its stated purpose: 'Volition means to have determination and a purpose.' It frames its mission in the tradition of major scientific discoveries — from penicillin to vaccines to genome editing — that share a determination to transform lives on a global scale. The company is focused on advancing the science of epigenetics. Its core platform, Nu.Q®, uses chromosomal structures such as nucleosomes and transcription factors as biomarkers. According to the company, all tests in its portfolio detect characteristic changes that occur from the earliest stages of disease, enabling early detection and potentially better monitoring of disease progression and a patient's response to treatment. VolitionRx has organized its commercial and clinical efforts around several product pillars: Nu.Q® Cancer, Nu.Q® Discover, Nu.Q® NETs and Nu.Q® Vet. The Nu.Q® technology is currently used for cancer applications in veterinary medicine, while the company continues to expand into human medicine through early clinical trials in cancer, sepsis and beyond. Nu.Q® NETs is a CE-marked diagnostic solution that clinicians can use to detect NETosis. Nu.Q® Vet is described as an affordable veterinary testing option. The company also sells recombinant nucleosomes and has developed Capture-Seq™ technology. The company has pursued clinical validation and commercialization across multiple fronts. It has participated in the launch of the DETECSEPS program in France, announced clinical validation of the Nu.Q® NETs biomarker, presented early-stage solid cancer detection data at the ESMO MAP conference, and entered a collaboration with Sysmex. It has also announced the publication of the first peer-reviewed paper on its new Capture-Seq™ technology and demonstrated a rapid, point-of-care finger-prick test. As a public company, VolitionRx Limited reports quarterly financial results and has taken corporate actions such as the pre-payment in full of a $7.5 million promissory note. The company describes itself as having a team of over 70 dedicated staff spanning a wide range of disciplines. Its leadership includes Cameron Reynolds as President and Group Chief Executive Officer, Terig Hughes as Group Chief Financial Officer, Gaetan Michel as Chief Operating Officer, and Jake Micallef as Chief Scientific Officer, among other executives and a board of directors.

• VolitionRx participates in the launch of the DETECSEPS program in France

• VolitionRx announces clinical validation of the Nu.Q® NETs biomarker

• VolitionRx presents early Stage I solid cancer detection at the ESMO MAP Conference

• VolitionRx announces collaboration with Sysmex

• Publication of first peer-reviewed paper on Capture-Seq™

• VolitionRx announces pre-payment in full of $7.5 million promissory note

A multi-national epigenetics company developing simple, easy-to-use, cost-effective blood tests for early detection and monitoring of life-altering diseases in humans and animals.

• Nu.Q® Cancer

  Cancer detection and monitoring tests based on nucleosome quantification.

• Nu.Q® Discover

  Research-use product pillar for nucleosome quantification.

• Nu.Q® NETs

  CE-marked diagnostic solution for detecting NETosis, associated with conditions such as sepsis.

• Nu.Q® Vet

  Affordable veterinary cancer testing for canine and feline cancer.

• Recombinant Nucleosomes

  Recombinant nucleosome products sold by the company.

• Capture-Seq™

  A technology developed by VolitionRx, with its first peer-reviewed paper published.

1. 1Volition - Early Diagnosis and Nucleosome Quantificationvolition.com
2. 2Our Company - Volitionvolition.com
3. 3Our Team - Volitionvolition.com
4. 4Resources - Volitionvolition.com
5. 5VolitionRx (United Kingdom) - Wikidatawikidata.org